BR112017028218A2 - ?comprimidos de liberação imediata contendo uma droga e processos para formação dos comprimidos? - Google Patents

?comprimidos de liberação imediata contendo uma droga e processos para formação dos comprimidos?

Info

Publication number
BR112017028218A2
BR112017028218A2 BR112017028218A BR112017028218A BR112017028218A2 BR 112017028218 A2 BR112017028218 A2 BR 112017028218A2 BR 112017028218 A BR112017028218 A BR 112017028218A BR 112017028218 A BR112017028218 A BR 112017028218A BR 112017028218 A2 BR112017028218 A2 BR 112017028218A2
Authority
BR
Brazil
Prior art keywords
tablets containing
drug
immediate release
release tablets
tableting processes
Prior art date
Application number
BR112017028218A
Other languages
English (en)
Inventor
Mauerer Alexander
Rezaei Hamid
Mantik Priscilla
Kothari Sanjeev
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of BR112017028218A2 publication Critical patent/BR112017028218A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/10—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of compressed tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2813—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

a presente divulgação se refere, de modo geral, a comprimidos de unidade de dosagem farmacêutica de liberação rápida contendo uma droga que é um inibidor da enzima de proteína quinase ativada por mitógeno, um preenchimento e um desintegrante e a processos para formação dos comprimidos. mais especificamente, a presente divulgação refere-se a comprimidos de unidade de dosagem farmacêutica contendo cobimetinibe, pelo menos um preenchimento, pelo menos um lubrificante e pelo menos um desintegrante e a métodos para preparar os comprimidos a partir de grânulos formados por granulação seca.
BR112017028218A 2015-06-30 2016-06-29 ?comprimidos de liberação imediata contendo uma droga e processos para formação dos comprimidos? BR112017028218A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562186556P 2015-06-30 2015-06-30
PCT/US2016/039960 WO2017004122A1 (en) 2015-06-30 2016-06-29 Immediate-release tablets containing a drug and processes for forming the tablets

Publications (1)

Publication Number Publication Date
BR112017028218A2 true BR112017028218A2 (pt) 2018-08-28

Family

ID=56373188

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017028218A BR112017028218A2 (pt) 2015-06-30 2016-06-29 ?comprimidos de liberação imediata contendo uma droga e processos para formação dos comprimidos?

Country Status (18)

Country Link
US (3) US10478400B2 (pt)
EP (3) EP4272735A1 (pt)
JP (3) JP6914202B2 (pt)
KR (1) KR102716253B1 (pt)
CN (2) CN108135854B (pt)
AR (2) AR105184A1 (pt)
AU (2) AU2016287422B2 (pt)
BR (1) BR112017028218A2 (pt)
CA (1) CA2987912C (pt)
ES (2) ES2871175T3 (pt)
HK (1) HK1254389A1 (pt)
HR (2) HRP20240045T1 (pt)
IL (2) IL256299B2 (pt)
MX (3) MX2017016163A (pt)
PL (2) PL3881833T3 (pt)
SI (2) SI3881833T1 (pt)
TW (3) TWI804919B (pt)
WO (1) WO2017004122A1 (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10751288B2 (en) * 2016-08-23 2020-08-25 New Jersey Institute Of Technology Dry processed surface coated engineering excipients
WO2018134254A1 (en) 2017-01-17 2018-07-26 Heparegenix Gmbh Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
BR112020006979A2 (pt) * 2017-10-13 2020-10-06 Unichem Laboratories Ltd composição farmacêutica estável, de liberação imediata para administração oral e processo para a preparação de composição farmacêutica estável, de liberação imediata, livre de desintegrante
CN110151763A (zh) * 2019-06-26 2019-08-23 深圳市第三人民医院 考比替尼作为制备治疗结核病药物中的应用
GB201913972D0 (en) 2019-09-27 2019-11-13 Univ Ulster Pharmaceutical Delivery Device and method of manufacture
BR112022024533A2 (pt) * 2020-06-19 2022-12-27 Glaxosmithkline Ip No 2 Ltd Formulação compreendendo daprodustat
JPWO2023145486A1 (pt) * 2022-01-28 2023-08-03

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2698560B1 (fr) * 1992-11-30 1995-02-03 Virbac Laboratoires Principes actifs pulvérulents stabilisés, compositions les contenant, leur procédé d'obtention et leurs applications.
TWI415635B (zh) * 2004-05-28 2013-11-21 必治妥施貴寶公司 加衣錠片調製物及製備彼之方法
CA2614468A1 (en) * 2005-07-15 2007-01-25 Teva Pharmaceutical Industries Ltd. Novel granulation process and granulate produced therefrom
WO2007044515A1 (en) 2005-10-07 2007-04-19 Exelixis, Inc. Azetidines as mek inhibitors for the treatment of proliferative diseases
US8146000B1 (en) 2005-10-07 2012-03-27 Goodwell Technologies, Inc. Integrated transactional workflows distributed across multiple contact centers
WO2008044111A1 (en) * 2006-10-13 2008-04-17 Pfizer Products Inc. Pharmaceutical formulation tablet
WO2009120844A2 (en) * 2008-03-26 2009-10-01 Teva Pharmaceutical Industries Ltd. Pharmaceutical compositions comprising insulin sensitizer and insulin secretagogue
CA2737528A1 (en) * 2008-09-17 2010-03-25 Mylan Laboratories, Inc. Granulates, process for preparing them and pharmaceutical products containing them
KR101429331B1 (ko) * 2009-06-22 2014-08-11 와이어쓰 엘엘씨 이부프로펜 나트륨 정제 및 이부프로펜 나트륨을 포함하는 제약 조성물의 제조 방법
EP2481411A1 (en) * 2011-01-27 2012-08-01 Ratiopharm GmbH Oral dosage forms for modified release comprising the JAK3 inhibitor tasocitinib
AR086647A1 (es) * 2011-06-03 2014-01-15 Hoffmann La Roche Metodos para tratar el mesotelioma con un compuesto inhibidor de la pi3k
WO2013082511A1 (en) * 2011-12-02 2013-06-06 Genentech, Inc. Methods for overcoming tumor resistance to vegf antagonists
KR20210033073A (ko) * 2011-12-27 2021-03-25 암젠 (유럽) 게엠베하 (+)-2-[1-(3-에톡시-4-메톡시-페닐)-2-메탄술포닐-에틸]-4-아세틸아미노이소인돌린-1,3-디온의 제제
MX2014014831A (es) * 2012-06-08 2015-02-12 Hoffmann La Roche Selectividad de mutante y combinaciones de un compuesto inhibidor de fosfoinositida 3 cinasa y agentes quimioterapeuticos para el tratamiento de cancer.
SG11201500582UA (en) * 2012-08-17 2015-04-29 Hoffmann La Roche Combination therapies for melanoma comprising administering cobimetinib and vemurafinib
PL2909188T3 (pl) 2012-10-12 2018-08-31 Exelixis, Inc. Nowy sposób wytwarzania związków do stosowania w leczeniu raka
ES2634020T3 (es) * 2013-03-06 2017-09-26 Novartis Ag Formulaciones de compuestos orgánicos
JP6568060B2 (ja) * 2013-07-12 2019-08-28 ピラマル エンタープライズイズ リミテッド 黒色腫の治療のための組合せ医薬
NZ715745A (en) * 2013-07-30 2017-06-30 Gilead Connecticut Inc Formulation of syk inhibitors
RU2018119749A (ru) * 2013-12-16 2018-11-09 Ф. Хоффманн-Ля Рош Аг Полиморфы 2-(4-(2-(1-изопропил-3-метил-1h-1,2,4-триазол-5-ил)-5,6-дигидробензо[f]имидазо[1,2-d][1,4]оксазепин-9-ил)-1h-пиразол-1-ил)-2-метилпропанамида, способы их получения и фармацевтические применения
AR105483A1 (es) * 2015-06-30 2017-10-11 Exelixis Inc Sal de fumarato cristalina de (s)-[3,4-difluoro-2-(2-fluoro-4-yodofenilamino)fenil][3-hidroxi-3-(piperidin-2-il)azetidin-1-il]-metanona

Also Published As

Publication number Publication date
EP4272735A1 (en) 2023-11-08
PL3316867T3 (pl) 2021-10-11
JP2021138716A (ja) 2021-09-16
HRP20240045T1 (hr) 2024-03-29
MX2022015606A (es) 2023-02-01
TW201705944A (zh) 2017-02-16
WO2017004122A1 (en) 2017-01-05
CN108135854A (zh) 2018-06-08
AU2022201067A1 (en) 2022-03-10
ES2871175T3 (es) 2021-10-28
CN108135854B (zh) 2022-03-11
CA2987912C (en) 2023-01-24
US20220339111A1 (en) 2022-10-27
AR121624A2 (es) 2022-06-22
HRP20210828T1 (hr) 2021-07-09
US10478400B2 (en) 2019-11-19
HK1254389A1 (zh) 2019-07-19
CN114177157A (zh) 2022-03-15
AU2016287422B2 (en) 2021-11-18
EP3881833B1 (en) 2023-11-01
SI3881833T1 (sl) 2024-03-29
TW202337463A (zh) 2023-10-01
PL3881833T3 (pl) 2024-05-13
MX2017016163A (es) 2018-08-15
JP2023071769A (ja) 2023-05-23
CA2987912A1 (en) 2017-01-05
JP2018519305A (ja) 2018-07-19
KR102716253B1 (ko) 2024-10-11
ES2969014T3 (es) 2024-05-16
AU2016287422A1 (en) 2018-01-04
US20200085749A1 (en) 2020-03-19
TWI804919B (zh) 2023-06-11
EP3316867B1 (en) 2021-03-10
JP7232284B2 (ja) 2023-03-02
AR105184A1 (es) 2017-09-13
JP6914202B2 (ja) 2021-08-04
IL303352A (en) 2023-08-01
US20180116966A1 (en) 2018-05-03
TW202206068A (zh) 2022-02-16
EP3316867A1 (en) 2018-05-09
CN114177157B (zh) 2024-08-02
MX2020013162A (es) 2021-02-18
IL256299B2 (en) 2023-11-01
SI3316867T1 (sl) 2021-08-31
IL256299B1 (en) 2023-07-01
EP3881833A1 (en) 2021-09-22
IL256299A (en) 2018-02-28
TWI795344B (zh) 2023-03-11
KR20180021814A (ko) 2018-03-05

Similar Documents

Publication Publication Date Title
BR112017028218A2 (pt) ?comprimidos de liberação imediata contendo uma droga e processos para formação dos comprimidos?
GT201600142A (es) Composiciones farmacéuticas que comprenden azd9291
BR112016024631A2 (pt) cápsulas antimicrobianas para conectores médicos
EP4349406A3 (en) Crystalline solid forms of 6-carboxy-2-(3,5-dichlorophenyl)-benzoxazole for use as a medicament
CL2015002608A1 (es) Compuesto de amino-pirazol y usos medicinales relacionados.
BR112017001192A2 (pt) composições de açúcar para preparação de tabletes por meio de compressão direta
CU24486B1 (es) Dispersión sólida amorfa que comprende taxano, tabletas comprendiendo la misma y método para prepararla
EA201692043A1 (ru) Лекарственная форма иммунодепрессанта
BR112019009159A2 (pt) comprimido de liberação controlada à base de álcool de polivinila e sua produção
CR20160438A (es) Dispersión sólida amorfa que comprende taxano, comprimido que comprende la misma, y método para su preparación
CA2863376A1 (en) Gastroretentive tablets
BR112017022846A2 (pt) combinação de dose fixa inviolável que proporciona rápida liberação de dois fármacos de partículas diferentes
BR112015029038A2 (pt) comprimido engolível, e, processo para preparação de um comprimido engolível
BR112018011476A2 (pt) formulação de vitamina
BR112017001000A2 (pt) composições de açúcar para preparação de comprimidos por compressão direta
BR112017001749A2 (pt) tipos de álcool polivinílico em pó, diretamente comprimíveis
BR112017020053A2 (pt) novo composto heterocíclico, método para a preparação do mesmo e composição farmacêutica compreendendo o mesmo
EA202090913A1 (ru) Композиция таблеток с модифицированным высвобождением, содержащая мирабегрон
BR112015021769A2 (pt) composições farmacêuticas compreendendo um agente ativo
BR112017022856A2 (pt) combinação de dose fixa inviolável que proporciona rápida liberação de duas drogas a partir de partículas
EA201890477A1 (ru) Инкапсулированная композиция финголимода
BR112017019364A2 (pt) dispersões sólidas
BR112016027580A8 (pt) composição farmacêutica compreendendo ceritinib, processo para preparação de um comprimido que compreende o mesmo, e uso de grânulos consistindo de ceritinib e um ligante
BR112018069440A2 (pt) forma de dosagem oral
BR112016026422A2 (pt) solução farmacêutica compreendendo dopamina para uso no tratamento da doença de parkinson

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]

Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO EM FUNCAO DA REVOGACAO DO ART. 229-C DA LEI NO 9.279, DE 1996, POR FORCA DA LEI NO 14.195, DE 2021

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B154 Notification of filing of divisional application [chapter 15.50 patent gazette]

Free format text: O PEDIDO FOI DIVIDIDO NO BR122023007239-1 PROTOCOLO 870230032339 EM 18/04/2023 15:06.

B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]